Inflammation Research

, Volume 48, Issue 10, pp 516–523

Anti-T cell strategies in asthma

Authors

  • O. M. Kon
    • Department of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London, SW3 6LY, UK, Fax +441713763138, e-mail: a.b.kay@ic.ac.uk
  • A. B. Kay
    • Department of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London, SW3 6LY, UK, Fax +441713763138, e-mail: a.b.kay@ic.ac.uk

DOI: 10.1007/s000110050496

Cite this article as:
Kon, O. & Kay, A. Inflamm. res. (1999) 48: 516. doi:10.1007/s000110050496

Abstract.

Chronic asthma is characterised by inflammation of the airways. Although corticosteroids are effective therapy, the risk benefit ratio is unacceptable in a minority of patients requiring chronic and high dose corticosteroid therapy because of adverse effects. There is accumulating circumstantial evidence that the CD4+ T-cell plays a central role in the pathogenesis of chronic asthma. Therapeutic strategies directed specifically at this cell type may offer a novel approach. Controlled clinical trials of cyclosporin A were effective in both chronic asthma and in a model of provoked asthma. Other immunomodulators such as FK506, rapamycin and mycophenolic acid may be useful given their modes of action on the T lymphocyte. The use of monoclonal antibody therapy directed towards these cells and T-cell peptide specific immunotherapy have been evaluated in preliminary studies and demonstrated promising results. Strategies targeting T cell co-stimulatory molecules and T-cell derived cytokines may be of therapeutic utility.

Key words: CD4+ T cells — Chronic asthma — Anti T cell antibodies — T cell peptides — Immunomodulators

Copyright information

© Birkhäuser Verlag, 1999